EP
ATRS

Eudaimonia Partners’s Antares Pharma, Inc. ATRS Stock Holding History

Eudaimonia Partners’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$54K – 916
2020
Q3 		$54K Sell
20,000
-5,800
-22% -$16.1K 0.01% 550
2020
Q2 		$71K Sell
25,800
-9,000
-26% -$25.1K 0.03% 423
2020
Q1 		$82K Buy
+34,800
New +$118K 0.04% 371

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Eudaimonia Partners's ATRS Position: Q4 2020 in Review

Eudaimonia Partners sold out of Antares Pharma, Inc. (ATRS) in Q4 2020, closing a stake of 20,000 shares — an estimated $54K sold.

Eudaimonia Partners first reported a position in ATRS in Q1 2020 and held it in 3 quarters. The position peaked at $82K in Q1 2020. 174 funds tracked by Wall St. Rank hold ATRS as of Q4 2020.

  • Eudaimonia Partners reported no remaining Antares Pharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Eudaimonia Partners sold 20,000 Antares Pharma, Inc. shares in Q4 2020, an estimated $54K.
  • Eudaimonia Partners first reported a position in Antares Pharma, Inc. in Q1 2020 and held it in 3 quarters.
  • Eudaimonia Partners's Antares Pharma, Inc. position peaked at $82K in Q1 2020.
  • 174 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2020.

Based on Eudaimonia Partners's 13F filing for Q4 2020, filed 18 Feb 2021.